The American Journal of Human GeneticsGeneticsPeer-reviewed journal article
A dementia-associated risk variant near TMEM106B alters chromatin architecture and gene expression
Michael D. GallagheriD, Marijan PosaviiD, Peng HuangiD, Travis L. Unger, Yosef BerlyandiD, Analise L. Gruenewald, Alessandra ChesiiD, Elisabetta ManduchiiD, Andrew D. WellsiD, Struan F.A. GrantiD, Gerd A. BlobeliD, Christopher D. BrowniD, Alice S. Chen‐PlotkiniD
Abstract
Neurodegenerative diseases pose an extraordinary threat to the worlds aging population, yet no disease-modifying therapies are available. While genome-wide association studies (GWAS) have identified hundreds of novel risk loci for neurodegeneration, the mechanisms by which these loci influence disease risk are largely unknown. Indeed, of the many thousands of SNP-trait associations identified by GWAS over the past ~10 years, very few are understood mechanistically. Here, we investigate the association of common genetic variants at the 7p21 locus with risk for the neurodegenerative disease frontotemporal lobar degeneration. We show that variants associated with disease risk correlate with increased brain expression of the 7p21 gene TMEM106B, and no other genes. Furthermore, incremental increases in TMEM106B levels result in incremental increases in lysosomal phenotypes and cell toxicity. We then combine fine-mapping, bioinformatics, and bench-based approaches to functionally characterize all candidate causal variants at this locus. This approach identified a noncoding variant, rs1990620, which differentially recruits CTCF, influencing CTCF-mediated long-range chromatin looping interactions between multiple cis-regulatory elements, including the TMEM106B promoter. Our findings thus provide an in-depth analysis of the 7p21 locus linked by GWAS to frontotemporal lobar degeneration, nominating a causal variant and a causal mechanism for allele-specific expression and disease association at this locus. Finally, we show that genetic variants associated with risk for neurodegenerative diseases beyond frontotemporal lobar degeneration are enriched in brain CTCF-binding sites genome-wide, implicating CTCF-mediated gene regulation in risk for neurodegeneration more generally.
- organism: human
- assay: DNA methylation
- assay: ChIP-seq
- research focus: gene regulatory network inference
- research focus: differential expression
- approach: statistical model
- approach: experimental assay
- Citations
- 109
- FWCI
- 6.67
- Field percentile
- top 3%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neurodegeneration risk variants promote lysosomal TMEM106B fibrilaccumulation
John Michael Replogle, Jordan D. Marks, … Michael Emmerson Ward·bioRxiv·Mar 28, 2026
- TMEM106B coding variant is protective and deletion detrimental in a mouse model of tauopathy
George A. Edwards, Caleb A. Wood, … Joanna L. Jankowsky·Acta NeuropathologicaPeer-reviewed·Mar 25, 2024
- Fine-mapping reveals four TMEM106B haplotypes associated with neurodegenerative risk and preserved cognition at extreme age
Alex Salazar, Niccoló Tesi, … Henne H. Holstege·medRxiv·Feb 2, 2025
- TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy.
Ruben Riordan, Aleen D. Saxton, … Brian C. Kraemer·bioRxiv·Jun 11, 2024
- Loss of TMEM106B exacerbates Tau pathology and neurodegeneration in PS19 mice
Tuancheng Feng, Huan Du, … Fenghua Hu·Acta NeuropathologicaPeer-reviewed·Mar 25, 2024
- TMEM106B C-Terminal fragment aggregation exacerbates α-synuclein and TDP-43 proteinopathy phenotypes.
Ruben Riordan, Aileen Saxton, … Brian C. Kraemer·bioRxiv·Oct 30, 2026